Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Assets (2021 - 2025)

Historic Assets for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $372.8 million.

  • ARS Pharmaceuticals' Assets rose 7132.41% to $372.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.8 million, marking a year-over-year increase of 7132.41%. This contributed to the annual value of $351.2 million for FY2024, which is 5058.79% up from last year.
  • ARS Pharmaceuticals' Assets amounted to $372.8 million in Q3 2025, which was up 7132.41% from $313.5 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Assets peaked at $382.2 million during Q1 2021, and registered a low of $61.4 million during Q4 2021.
  • Its 5-year average for Assets is $282.4 million, with a median of $281.4 million in 2022.
  • Examining YoY changes over the last 5 years, ARS Pharmaceuticals' Assets showed a top increase of 35802.01% in 2022 and a maximum decrease of 2311.57% in 2022.
  • Over the past 5 years, ARS Pharmaceuticals' Assets (Quarter) stood at $61.4 million in 2021, then soared by 358.02% to $281.4 million in 2022, then decreased by 17.14% to $233.2 million in 2023, then skyrocketed by 50.59% to $351.2 million in 2024, then grew by 6.17% to $372.8 million in 2025.
  • Its Assets stands at $372.8 million for Q3 2025, versus $313.5 million for Q2 2025 and $327.3 million for Q1 2025.